Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22901815 | 1.00 | ALDH1A1 (0.70) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL9533498 | 0.78 | ALDH1A1 (0.81) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL725331 | 0.75 | ALDH1A1 (0.75) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL3335215 | 0.74 | ALDH1A1 (0.72) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL3335212 | 0.74 | ALDH1A1 (0.72) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL16846230 | 0.70 | ALDH1A1 (0.65) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL376626 | 0.70 | MAPT (1.00) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL376625 | 0.70 | MAPT (1.00) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL16825841 | 0.70 | ALDH1A1 (0.71) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL16825840 | 0.70 | ALDH1A1 (0.71) | ALDH1A1KDM4EMAPTHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025889-A1 | PROCESS FOR THE PRODUCTION OF 5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYL-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE | Oncoarendi Therapeutics S.A. (PL) | 2024-01-25 | — | — | US | disclosed |
| US-20240025889-A1 | PROCESS FOR THE PRODUCTION OF 5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYL-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE | Oncoarendi Therapeutics S.A. (PL) | 2024-01-25 | — | — | US | disclosed |
| US-11746107-B2 | Process for the production of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methyl-morpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine | MOLECURE S.A. (PL) | 2023-09-05 | — | — | US | disclosed |
| US-11746107-B2 | Process for the production of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methyl-morpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine | MOLECURE S.A. (PL) | 2023-09-05 | — | — | US | disclosed |
| US-20210147401-A1 | PROCESS FOR THE PRODUCTION OF 5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYL-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE | Oncoarendi Therapeutics S.A. (PL) | 2021-05-20 | — | — | US | disclosed |
| WO-2021059220-A1 | PROCESS FOR THE PRODUCTION OF 5-(4-((2 S,5 S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1 H-1,2,4-TRIAZOL-3-AMINE | Oncoarendi Therapeutics S.A. (PL) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025889-A1 | PROCESS FOR THE PRODUCTION OF 5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYL-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE | NT5C, HTR5A, NT5C3B | ALDH1A1 1964/4885KDM4E 307/4885MAPT 1527/4885 |
| US-20210147401-A1 | PROCESS FOR THE PRODUCTION OF 5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYL-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE | NT5C, HTR5A, NT5C3B | ALDH1A1 1964/4885KDM4E 307/4885MAPT 1527/4885 |
| US-11746107-B2 | Process for the production of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methyl-morpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine | NT5C, HTR5A, NT5C3B | ALDH1A1 1964/4885KDM4E 307/4885MAPT 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.